PHAXIAM THERAPEUTICS (ERYPP) — key financial figures for fiscal year 2023 (in EUR), standardized from XBRL/iXBRL filings by Hub-Equity:

Net Income/Loss (FY2023)

-€23.5M

Total Assets (FY2023)

€51.3M

Total Equity (FY2023)

€25.6M

Cash Flows from Operating Activities (FY2023)

-€24.4M

Source: PHAXIAM THERAPEUTICS annual_report filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.